Cargando…

Upstream therapeutic strategies of Valsartan and Fluvastatin on Hypertensive patients with non-permanent Atrial Fibrillation (VF-HT-AF): study protocol for a randomized controlled trial

BACKGROUND: Previous studies regarding rhythm control in patients with atrial fibrillation (AF) could not sufficiently demonstrate the efficacy of available anti-arrhythmic drugs. ‘Upstream therapy’ has emerged as a potential strategy for the prevention and treatment of AF. The use of angiotensin II...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qi, Wen-Wei, Liu, Tong, Xu, Gang, Li, Li-Feng, Liang, Ying-Zi, Ye, Lan, Li, Guang-Ping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4528391/ https://www.ncbi.nlm.nih.gov/pubmed/26248619 http://dx.doi.org/10.1186/s13063-015-0836-5

Ejemplares similares

Combined treatment with valsartan and fluvastatin to delay disease progression in nonpermanent atrial fibrillation with hypertension: A clinical trial
por: Zhao, Zhiqiang, et al.
Publicado: (2020)

Upstream Therapy for Atrial Fibrillation Prevention: The Role of Sacubitril/Valsartan
por: De Vecchis, Renato, et al.
Publicado: (2020)

Fluvastatin therapy could not decrease progression of paroxysmal atrial fibrillation in non-valvular disease patients
por: Tan, Qiang, et al.
Publicado: (2017)

Clinical Characteristics, Management, and Control of Permanent vs. Nonpermanent Atrial Fibrillation: Insights from the RealiseAF Survey
por: Murin, Jan, et al.
Publicado: (2014)

Sacubitril/valsartan attenuates atrial structural remodelling in atrial fibrillation patients
por: Yang, Liu, et al.
Publicado: (2022)

Indonesian registry on atrial fibrillation (OneAF)
por: Raharjo, Sunu Budhi, et al.
Publicado: (2021)

Effects of ACEI/ARB or CCB use on atrial fibrillation in hypertensive patients following permanent pacemaker implantation
por: Liu, Zhijie, et al.
Publicado: (2023)

A Depth-Dependent Integrated VF Simulation for Analysis and Visualization of Glaucomatous VF Defects
por: Liu, Ping, et al.
Publicado: (2020)

A Low-Dose Combination of Fluvastatin and Valsartan: A New “Drug” and a New Approach for Decreasing the Arterial Age
por: Janić, Miodrag, et al.
Publicado: (2015)

Atrial fibrillation virtual ward: reshaping the future of AF care
por: Kotb, A, et al.
Publicado: (2022)

Information Theory and Atrial Fibrillation (AF): A Review
por: Dharmaprani, Dhani, et al.
Publicado: (2018)

5-HT and Intraplatelet 5-HT: a potential upstream regulator of YAP in liver regeneration
por: He, Chao, et al.
Publicado: (2019)

A Combination of Low Doses of Fluvastatin and Valsartan Decreases Arterial Stiffness in Patients After Myocardial Infarction: A Pilot Study
por: Hanžel, Jurij, et al.
Publicado: (2015)

Expression of Longevity Genes Induced by a Low-Dose Fluvastatin and Valsartan Combination with the Potential to Prevent/Treat “Aging-Related Disorders”
por: Janić, Miodrag, et al.
Publicado: (2019)

Korean Atrial Fibrillation (AF) Network: Genetic Variants for AF Do Not Predict Ablation Success
por: Choi, Eue-Keun, et al.
Publicado: (2015)

Sacubitril/Valsartan Improves Left Atrial and Left Atrial Appendage Function in Patients With Atrial Fibrillation and in Pressure Overload-Induced Mice
por: Suo, Ya, et al.
Publicado: (2019)

Enantiospecific Pharmacogenomics of Fluvastatin
por: Hirvensalo, Päivi, et al.
Publicado: (2019)

The application and mechanism of Chinese medicine in the upstream treatment of atrial fibrillation
por: Liu, Min, et al.
Publicado: (2023)

Re‐CHARGE‐AF: Recalibration of the CHARGE‐AF Model for Atrial Fibrillation Risk Prediction in Patients With Acute Stroke
por: Ashburner, Jeffrey M., et al.
Publicado: (2021)

The Difference in Pharmacokinetics and Pharmacodynamics between Extended-Release Fluvastatin and Immediate-Release Fluvastatin in Healthy Chinese Subjects
por: Xu, H. R., et al.
Publicado: (2012)

Atrial Fibrillation in Patients with Permanent VVI Pacemakers: Risk Factors for Atrial Fibrillation
por: Cho, Jeong Gwan, et al.
Publicado: (1997)

Hospitalizations in patients with atrial fibrillation: an analysis from ROCKET AF
por: DeVore, Adam D., et al.
Publicado: (2016)

Atrial fibrillation and heart failure- results of the CASTLE-AF trial
por: Shah, Syed Raza, et al.
Publicado: (2018)

Atrial Fibrillation (AF) in Endurance Athletes: a Complicated Affair
por: Stergiou, Dimitrios, et al.
Publicado: (2018)

In-Hospital Mortality Among Critically Ill Patients With Atrial Fibrillation (AF) Versus Patients Without AF
por: Mehreen, Tooba, et al.
Publicado: (2021)

Effect of valsartan on atrial fibrillation recurrence following pulmonary vein isolation in patients
por: CUI, YINGKAI, et al.
Publicado: (2015)

Progression and regression in the left atrial substrate in patients with atrial fibrillation: the PROGRESS-AF study
por: Marcon, L, et al.
Publicado: (2023)

Comparisons of Rivaroxaban Following Different Dosage Criteria (ROCKET AF or J‐ROCKET AF Trials) in Asian Patients With Atrial Fibrillation
por: Chan, Yi‐Hsin, et al.
Publicado: (2019)

Engagement of atrial fibrillation patients with the AF-EduApp, a new mobile application to support AF management
por: Knaepen, Lieselotte, et al.
Publicado: (2023)

Improving Arterial Wall Characteristics in Patients After Myocardial Infarction with a Very Low Dose of Fluvastatin and Valsartan: A Proof-of-Concept Study
por: Veselič, Martina Turk, et al.
Publicado: (2018)

Continuous monitoring after atrial fibrillation ablation: the LINQ AF study
por: Wechselberger, Simon, et al.
Publicado: (2018)

Monitoring for AF: Identifying the Burden of Atrial Fibrillation and Assessing Post-Ablation
por: Passman, Rod S.
Publicado: (2017)

Atrial fibrillation and comorbidities: Clinical characteristics and antithrombotic treatment in GLORIA-AF
por: Kozieł, Monika, et al.
Publicado: (2021)

Spironolactone in Atrial Fibrillation With Preserved Cardiac Fraction: The IMPRESS‐AF Trial
por: Shantsila, Eduard, et al.
Publicado: (2020)

Aldosterone Antagonism in Atrial Fibrillation: Implications for AF‐Predominant HFpEF
por: Ho, Jennifer E.
Publicado: (2020)

Symptomatic and Asymptomatic Patients in the Polish Atrial Fibrillation (POL-AF) Registry
por: Kiliszek, Marek, et al.
Publicado: (2021)

Age-dependent risk for thromboembolism in atrial fibrillation: The Fushimi AF registry
por: Esato, Masahiro, et al.
Publicado: (2022)

Increased mortality in patients with secondary diagnosis of atrial fibrillation: Report from Chinese AF registry
por: Shao, Xing‐Hui, et al.
Publicado: (2020)

Effect of Sacubitril-Valsartan on Restoration and Maintenance of Sinus Rhythm in Patients With Persistent Atrial Fibrillation
por: Chen, Qingsong, et al.
Publicado: (2022)

Genetic and neuronal regulation of sleep by neuropeptide VF
por: Lee, Daniel A, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ooljl50jmodaak9v118he2ah3d